DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS
Author(s): ,
Jing Wang
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
,
Run-Qing Lu
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
,
Xiao-Su Zhao
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
,
Xiao-Jun Huang
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Peking-Tsinghua Center for Life Sciences,china,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
,
Guo-Rui Ruan
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
Hao Jiang
Affiliations:
Peking University Institute of Hematology,Peking University People’s Hospital,beijing,China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases,china,beijing,China
EHA Library. wang J. Jun 15, 2019; 266657; PS1040
Dr. Jing wang
Dr. Jing wang
Contributions
Abstract

Abstract: PS1040

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Acute myeloid leukemia (AML) patients with biallelic CEBPA mutations have a 30-50% relapse rate after standard chemotherapy.

Aims
This study established the value of multiparameter flow cytometric minimal residual disease (MFC-MRD) detection and compares the outcomes of allogeneic stem cell transplantation (allo-HSCT) versus chemotherapy in adult biallelic CEBPA AML patients after relapse.

Methods
From March 2014 to September 2018, 120 patients with newly diagnosed acute myeloid leukemia with biallelic CEBPA mutations were treated with chemotherapy. MRD was detected by MFC after each cycle of induction and consolidation chemotherapy and every 3 months later.

Results
Median age was 38 (16-69) years. One hundred (100%) achieved complete remission (CR) including 110 patients (91.7%) who achieved it with only 1 induction course. The median follow-up was 27.5 (3-62) months. The 3-year Cumulative incidence of relapse (CIR), disease-free survival (DFS) and overall survival (OS) were 35.7%, 62.2%, and 81.7% respectively. MRD turned to negative at the median follow-up of 2 (1-7) months. MRD positive after 2 consolidation cycles was the adverse factor of CIR (73.6% vs. 25.9%, P<0.001), DFS (26.4% vs. 71.2%, P<0.001) and OS (58.5% vs. 88.7%, P=0.002). MRD sustained positive status after 2 consolidation cycles and MRD negative status losed in 9 and 22 patients, were the adverse factors of CIR (100% vs. 28.2%, P<0.001; 95.5% vs. 4.5%, P<0.001; respectively) DFS (0 vs. 69.0%, P<0.001; 4.5% vs. 91.6%, P<0.001; respectively) and OS (33.3% vs. 88.2%, P<0.001; 64.5% vs. 96%, P<0.001; respectively), eventually 100% and 95.5% relapsed at the median follow-up of 6 (3-15) and 11(3-26) months respectively. Multivariate analysis showed that MRD sustained positive status after 2 consolidation cycles and MRD negative status loses was the favorable factor of CIR, DFS and OS. (HR=50.9, 95%CI: 15.1-167.8, P<0.001; HR=24.0, 95%CI: 9.8-58.8, P<0.001; HR=11.1, 95%CI: 3.2-39.1, P<0.001; respectively). In totally 33 patients relapsed at the median follow-up of 9 (3-26) months, 3 patients give up, 18 (60.0%) patients achieved CR2 after induction again. 15 CR2 and 4 non-remission patients underwent allo-HSCT achieved superior 3-year OS (83.0% vs 5.1%; p= 0.034; 75.0% vs 0%; p=0.006; respectively) than did consolidation chemotherapy.

Conclusion
MRD sustained positive status after 2 consolidation cycles and MRD negative status loses could predict relapse, and allo-HSCT is superior to chemotherapy after relapse.

Session topic: 4. Acute myeloid leukemia - Clinical

Keyword(s): Allogeneic hematopoietic stem cell transplant, AML, Chemotherapy, MRD

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies